Zentalis Pharmaceuticals, Inc. (ZNTL)
2025-06-30 | 2025-03-31 | 2024-06-30 | ||
|---|---|---|---|---|
| License revenue | - | - | - | |
| Restructuring | - | 7,796 | - | |
| Research and development | 27,610 | 27,247 | 48,386 | |
| General and administrative | 8,448 | 10,580 | 16,762 | |
| Total operating expenses | 36,058 | 45,623 | 65,148 | |
| Loss from operations | -36,058 | -45,623 | -65,148 | |
| Investment and other income (expense), net | 9,184 | -2,656 | -22,863 | |
| Net loss before income taxes | -26,874 | -48,279 | - | |
| Income tax expense | - | - | 266 | |
| Net loss before income taxes | - | - | -88,011 | |
| Net loss | -26,874 | -48,279 | -88,277 | |
| Net loss attributable to noncontrolling interests | - | - | - | |
| Net loss attributable to zentalis | -26,874 | -48,279 | -88,277 | |
| Net loss per common share outstanding, basic (in dollars per share) | -0.37 | -0.67 | -1.24 | |
| Net loss per common share outstanding, diluted (in dollars per share) | -0.37 | -0.67 | -1.24 | |
| Weighted average number of common shares outstanding, basic (in shares) | 71,992,000 | 71,678,000 | 71,040,000 | |
| Weighted average number of common shares outstanding, diluted (in shares) | 71,992,000 | 71,678,000 | 71,040,000 | |